ASX Announcement

Medibio Limited – 5 October 2018

Medibio Provides Updated Company Presentation

Sydney, Australia and Minneapolis, MN USA – 5 October 2018: Medibio Limited (**MEB** or the **Company**)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, is pleased to release an updated company presentation, which is attached to this announcement. The presentation will be used for a series of meetings in the coming weeks.

- ENDS -

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au

Further Information: Website: www.medibio.com.au

Medibio Enquiries:
Josh Purdy
Senior Public Relations Manager
Medibio Limited
josh.purdy@medibio.com.au
T: +1 952 314 1216

Australian Media Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231

medibio

Investor Presentation

October 2018

FORWARD LOOKING STATEMENTS

The purpose of the presentation is to provide an update of the business of Medibio Limited **(ASX:MEB) (OTCQB: MDBIF)**. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies(or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfillment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

medibio

medibio

The mental health technology company leveraging objective digital biomarkers for products and services that assist in screening, diagnosing, monitoring, and managing of depression and other mental health conditions.

THE CHALLENGE

In **Organizations**

Mental Health in the Workplace

Only **3.5***

of employees will utilize their employee assistance program,
at an approximate cost of

$2.1 MILLION

*Each figure represents 10

90%

of employees in severe ranges will be untreated

2.9 MILLION Hours per year of lost productivity

20% of employees meet the diagnostic criteria for depression

2.30 return on investment through early and effective targeted interventions

In **Society**

Stigma and lack of access are prevalent globally

21 million suicide attempts from mental illness

Of those, nearly **1 million** are successful

In 2015, suicide was the

2ND leading cause of death among 15 to 29 year-olds globally

300 MILLION suffer from depression

7.7 MILLION PTSD sufferers in the United States alone

1 in 13 suffer from anxiety

In the **Health Care System**

Only **1 psychiatrist per 100,000 people** in over half the countries in the world

40% of countries have less than one hospital bed reserved for mental disorders **per 10,000 people**

Out of **350 million** patients globally **< 7%** receive optimal treatment

50% are never diagnosed

30% are incorrectly diagnosed

$94.5 BILLION direct cost to treat Major Depressive Disorder (MDD) annually in the USA

$12.6 BILLION direct cost to treat depression annually in Australia

medibio

THE OPPORTUNITY

CORPORATE HEALTH

Providing personalised solutions in employee and organizational mental health.

STRESS

~64 million lives[1]

CONSUMER HEALTH

Empowering consumers to track and manage mental health.

STRESS

~266 million lives[2]

INTEGRATED HEALTH

Designing clinical decision support systems that enable clinicians to monitor and manage their patient populations.

DEPRESSION

~450 million lives[3]

1. Based on employment in USA and Australia
2. Based on adult population in USA and Australia
3. World Health Organization's global population of mental disorders

medibio

THE SOLUTION

Medibio ZBLE

2016

Medibio inform

May 2018

Medibio ilumen™

October 2018

Professional Portal

Cloud-based, HIPAA-compliant platform allowing providers to use objective digital biomarker data to support prospective clinical decisions and patient care.

Features include:

- **Baseline and longitudinal views of data points - circadian patterns of cardio, autonomic, and sleep functions.**
- **Aide in the screening, diagnosing, monitoring, and management of Mental Health.**
- **High resolution Index mental health biometric data analytics**



Pending FDA Approval

medibio

World Mental Health Day
10 OCTOBER 2018

This global crisis needs a hero. Medibio has championed an objective approach to understanding and treating mental health conditions like depression, anxiety, and stress. We continue to build data-driven, biometric-based solutions to shine a light on what subjective diagnosis cannot.

World Mental Health Day 2018 marks the release of ilumen, our corporate wellness platform developed to help companies address mental wellness and offer support to their workforce. The world needs a new way to talk about, understand, screen, diagnose and monitor mental illness – and we believe that way is

#poweredbyscience





ilumen™
Corporate Health Product

An objective digital biometric analysis and mental wellness assessment provided to the employee, paid for by their employer.

medibio

2 Based on adult population in USA and Australia

REAL-TIME ORGANIZATIONAL DASHBOARD

Organizational Dashboard

Status: **LIVE**

Filtering results by:

GENDER: MALE / FEMALE / NON-BINARY

AGE: 18-24 / 25-34 / 35-44 / 45-54 / 55+



Benefits:

- Detailed analytics to Corporate Customers at Organizational level
- De-identified, aggregate data to enable informed decision making
- Ability to filter and view demographical subsections (eg. Females, aged 18-35)
- Improve team performance and employee well-being

medibio

WORKFORCE WELLNESS
FROM THE INSIDE OUT

ASSESS



CONNECT

DISCOVER

from
$5-$15 per capita

Entry Level

from
$60 per annum

Subscription Based

THE CHALLENGES

In any workforce there are various levels of stress that can affect individual/team mental wellness.

Employers are

- Increasing pressure to meet internal/external targets and promoting high performing culture
- Requiring higher levels of mental fitness & time requirements at work and at home
- Expecting frequent travel and project deployment

...While managing

- Wide geographical distribution
- Turnover
- Well-being programs that aren't data-driven or specific to your organization

HOW IT WORKS

Employees:

- Employees use a wearable device for objective digital biometrics tracked over time
- Employee has access to mental wellness assessments via mobile or web
- Proactively learn about strategies to better cope with managing life at work, personal development plans, stress, and strain
- Employees empowered and enabled to measure, monitor, and improve wellness

Organizations:

- Acquire Dynamic understanding - know what your workforce needs AND how to help
- Optimize workforce performance, minimize risk, and offer better care for employees

OUTCOMES

Employees:

- Track and monitor wellness
- Improve through tailored resources
- Identify positive influences of personal lifestyle modifications

Organizations:

- Access a de-identified dashboard of employee well-being
- Make informed decisions based on workforce data
- Monitor impact of decisions made, programs implemented
- Provide metrics on workforce capability to clients, suppliers, insurers etc.

medibio

THE SCIENCE

PIONEERING RESEARCH
MENTAL ILLNESS AND BIOMARKERS IN THE HUMAN BODY

Physiology

Our approach exploits features of cardiovascular physiology influenced directly by the autonomic nervous system and susceptible to disruption during sleep, as a source of biometrics that correlate with onset and existence of mental dysfunction.

20 plus years*
of data collected

Data Science

Our approach focuses on using Artificial Intelligence to monitor mental illness types (such as depression, PTSD, anxiety and stress) and potential physiological metrics, so we can predict irregularity and future recurrent episodes.

A comprehensive patent suite
CHR, technology, and diagnostics

The relationship between psychiatric illness and the circadian pattern of heart rate. Hans G . Stampfer, Australian and New Zealand Journal of Psychiatry 1998; 32:187-198.

medibio

SCIENTIFIC ADVISORY BOARD

External Advisors:

Martin Chapman, MBBS FRANZCP
Psychiatrist and Fellow of the **Royal Australian and New Zealand College of Psychiatrists**. As a medical administrator he has worked in both hospital and community settings in private and government sectors. His clinical practice is in the area of treatment resistant mood and anxiety disorders. He has taught in undergraduate and postgraduate Psychiatry with a focus in assisting primary care physicians in their management of mental health conditions. He has an interest in mental health system development and the role of new technologies in streamlining and providing clinical decision support.

Joel R. Ehrenkranz, M.D.
Endocrinologist on the faculty of the **University of Colorado School of Medicine** and a biotech entrepreneur in Salt Lake City, Utah. Dr. Ehrenkranz received his M.D. degree from Stanford and trained in internal medicine at Columbia University, neurology at Memorial Sloan Kettering Cancer Center, and endocrinology at the National Institutes of Health.

Mark A. Frye, M.D.
Chair of the Department of Psychiatry and Psychology at **Mayo Clinic**. He also serves as director of the Mayo Clinic Depression Center. Dr. Frye received his M.D. from the University of Minnesota and completed his psychiatric training at the Semel Institute for Neuroscience and Human Behavior at the David Geffen School of Medicine at UCLA. He subsequently completed a fellowship at the National Institute of Mental Health in Bethesda, Maryland with a research focus on the neurobiology of treatment resistant depression and bipolar disorder.

Lawrence Hunter, Ph.D.
Professor at the **University of Colorado** and directs the Computational Bioscience Program. He earned his degrees from Yale University, including B.A. in Psychology (cum laude); M.S. and M. Phil. and Ph.D. in Computer Science.

Wallace Mendelson, M.D.
Psychiatrist and author, and was formerly **Professor of Psychiatry and Clinical Pharmacology**, and director of the **Sleep Research Laboratory**, at the **University of Chicago**. Dr. Mendelson earned an MD degree from Washington University School of Medicine in St. Louis and completed a residency in psychiatry there as well. He has held professorships at Ohio State University and the State University of New York at Stony Brook, was Chief of the Section on Sleep Studies at the National Institute of Mental Health in Bethesda, MD, and Director of the Sleep Disorders Center at the Cleveland Clinic.

Marie Casey Olseth, M.D.
Currently in private practice as a Board Certified Adult Psychiatrist in the group practice that she owns. She earned her of Medicine degree from the University of Minnesota Medical School and completed her residency in General Psychiatry at the University of Minnesota and University of Wisconsin, Madison.

Giampaolo Perna, M.D., Ph.D.
Currently Chair of the Department of Clinical Neurosciences at **San Benedetto Menni Hospital of the Hermanas Hospitalarias (Como Lake)** and Academic Coordinator of Mental Health and Adjunct Professor at **Humanitas University (Milan)**, in Italy. He earned his degree in Medicine and Surgery at the State University of Milan, followed by Ph.D. and completed a residency in Psychiatry there as well. He is the Chair of WPA section on personalized psychiatry and Co-editor in chief of the Elsevier Journal “Personalized Medicine in Psychiatry”.

Internal Advisors:

Archie Defillo, M.D.
Currently the Chief Medical Officer at **Medibio Limited**. He has over 25 years of clinical experience with neurological diseases. For the past 13 years his efforts have been focused in neurological research. His research interests include cerebrovascular, stroke, neuro-trauma, brain oxygenation, metabolism and autonomic dysfunction.

Franklyn Prendergast, M.D., Ph.D.
Currently a director on the **Medibio Limited** board and chair of the Scientific Advisory Board. Previously, he was the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, to its Physician Advisory Board.

Dr. Prendergast earned his medical degree with honors from the University of West Indies. He attended Oxford University as a Rhodes Scholar, where he earned his masters degree in Physiology. After completing residency in Internal medicine at The Mayo Clinic in Rochester, Minnesota he earned a doctorate degree Biochemistry from the University of Minnesota/Mayo Graduate School.

Positions held: Chair, Department of Biochemistry and Molecular Biology; Director for Research Mayo Clinic (Rochester) (1989-1992). Board of Governors Mayo Clinic in Rochester; Mayo Clinic Board of Trustees (1992-2009); Mayo Clinic Board of Governors (1999-2006). Mayo Distinguished Investigator; Emeritus Director, Mayo Clinic Comprehensive Cancer Center and Mayo Center for Individualized Medicine.

In addition to his current role as a director on the Medibio board and chair of the Scientific Advisory Board, Dr. Prendergast holds numerous appointments with Industry and Extramural academic affiliations. He has extensive interactions over many years with National Institutes of Health (NIH): Board of Advisors for the Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of the National Cancer Institute; and the National Cancer Advisory Board.

medibio

SCIENTIFIC & CLINICAL DEVELOPMENT PROCESS



CLINICAL BACKGROUND

PAST / PRESENT STUDIES	PARTNERS	ACCURACY	STUDY PURPOSE
Prospective Clinical Validation Trial **DX04 DEPRESSION - Prospective Study** May 2018 220 patients	8 clinical study partners	**70% (56-84%)**	Prospective, blinded, case controlled, cross sectional clinical validation study to support the FDA De Novo submission as an aide in the diagnosis of depression in a normal environment
Retrospective Data Analysis **Retrospective PSG+HRV in sleep lab for DEPRESSION** November 2016 889 patients	Ottawa University	86%	Retrospective, un-blinded analysis to identify depressed from non-depressed subjects in a controlled sleep lab environment using PSG + HRV
Proof of Concept **MACH-3 Depression - Prospective study** August 2017 60 patients	JOHNS HOPKINS MEDICINE	82%	Prospective, proof of concept study using HRV to diagnose depression In a primary care setting
MACH-2 DEPRESSION - retrospective study December 2016 26 patients	JOHNS HOPKINS MEDICINE	81%	Retrospective hypothesis study to identify depressed patients
Foundational Learning **SLEEP STAGING Observational Study using ECG Data** June 2016 7,500 subject sleep records	JOHNS HOPKINS MEDICINE	86-95%	Retrospective data analysis to identify sleep staging using ECG data

Versus 33-50% – Diagnostic accuracy in the Primary Care Setting[1]
(1) Depression in Primary Care Vol 1: U.S. Department of Health

medibio

CLINICAL VALIDATION
DX04 FDA STUDY

		ACCURACY	CONFIDENCE INTERVAL (95%)
Medibio DX04		**70%**	**56-84%**
Physician Inter-Rater Reliability[1,2]		**48-64%**	

1. Mulsant BH., et al. Inter-rater reliability in clinical trials of depressive disorders. AM J Psychiatry. 2002 Sept: 159(9): 1598-1600.
2. Einfeld S., et al. Inter-Rater Reliability of the Diagnoses of Psychosis and Depression in Individuals with Intellectual Disabilities: 2007 Sept: 20 (5): 384-390

medibio

REGULATORY VALIDATION & PUBLICATIONS


medibio

AUTONOMIC / CIRCADIAN
HEART AND SLEEP MANIFESTATION
IN MENTAL ILLNESS

05 May 2018

Archie Defillo, M.D.
Chief Medical Officer
Medibio Corporate
Medibio Ltd

OFFICE LOCATIONS

United States Global Headquarters
8696 Eagle Creek Circle
Savage, MN 55378

Australia
Suite 28, 25 Claremont Street
South Yarra VIC 3141

Australia
246 Churchill Avenue
Subiaco WA 6008


EC-CERTIFICATE
(Product quality assurance)

This is to certify that the company

Medibio Limited
8646 Eagle Creek Circle,
Suite 211
Savage, MN 55378
United States of America

has implemented and maintains a quality assurance system which applies to the final controls of the products.

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that this quality assurance system fulfills the requirements of

Annex VI of Council Directive 93/42/EEC concerning medical devices

with respect to the following medical devices:

Depression Diagnostic Aid V1.0 Class IIa

The manufacturer is subject to surveillance according to Annex VI, Section 4. The CE marking with the Notified Body Identification Number (0297) may be affixed on the devices listed in the certificate. The certificate is in the case of class II(m) devices ((m) = class I devices with a measuring function) limited to the aspects of manufacture concerned with the conformity of the products with the metrological requirements.

Certificate registration no.	532495 MR6
Certificate unique ID	170693057
Effective date	2018-05-02
Expiry date	2022-12-19
Frankfurt am Main	2018-05-02

DQS Medizinprodukte GmbH

Sigrid Uhlemann
Managing Director

Dr. Thomas Feldmann
Head of Certification Body

August-Schanz-Straße 21, 60433 Frankfurt am Main,
Tel. +49 (0) 69 95427-300, medical.devices@dqs-med.de

DQS Medizinprodukte GmbH is a Notified Body according to Council Directive 93/42/EEC concerning medical devices with the identification Number 0297.


Australian Government
Department of Health
Therapeutic Goods Administration

Australian Register of Therapeutic Goods Certificate

Issued to
Medibio Ltd
for approval to supply

Medibio Ltd - Psychological assessment system application software

ARTG Identifier	304642
ARTG Start date	18/06/2018
Product Category	Medical Device included Class IIa
GMDN	58290
GMDN Term	Psychological assessment system application software
Intended Purpose	A software program intended to characterise cardiac autonomic, sleep, and activity patterns to aid in determining the psychological profile of a patient.

Manufacturer Details	Address	Certificate number(s)
Medibio Ltd	8646 Eagle Creek Circle Suite 211 Savage, MN, 55378 United States Of America	DV-2018-MC-08146-1

ARTG Standard Conditions
The above Medical Device Included Class IIa has been entered on the Register subject to the following conditions:
- The inclusion of the kind of device in the ARTG is subject to compliance with all conditions placed or imposed on the ARTG entry; Refer Part 4-5, Division 2 (Conditions) of the Therapeutic Goods Act 1989 and Part 5, Division 5.3 (Conditions) of the Therapeutic Goods (Medical Devices) Regulations 2002 for relevant information.
- Breaching conditions of the inclusion related to the device of the kind may lead to suspension or cancellation of the ARTG entry; may be a criminal offence; and civil penalties may apply.

Products Covered by This Entry
1. Psychological assessment system application software

Product Specific Conditions
No specific conditions have been recorded against this entry.

Therapeutic Goods Administration
PO Box 100, Woden ACT 2606 Australia

ARTG Identifier: 304642
ARTG Start Date: 18/06/2018

TGA
Health Safety
Regulation

CE


CERTIFICATE

This is to certify that the company

Medibio Limited
8646 Eagle Creek Circle,
Suite 211
Savage, MN 55378
United States of America

with the organizational units/sites as listed in the annex

has implemented and maintains a **Quality Management System**.

Scope:
Design, Development, Production and Distribution of Information Systems, Decision Support, Clinical.

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that the management system fulfills the requirements of the following standard:

ISO 13485 : 2003 + Cor. 1 : 2009

Certificate registration no.	532495 MP23CMDR
Certificate unique ID	170693056
Effective date	2017-12-20
Expiry date	2018-12-31
Frankfurt am Main	2017-12-20

DQS Medizinprodukte GmbH

Sigrid Uhlemann
Managing Director

Maxim Shkolnikov
Product Manager

Accredited Body: DQS Medizinprodukte GmbH, August-Schanz-Str. 21, 60433 Frankfurt a. M., Germany 1 / 2

ISO
13485

FDA

[anticipated De Novo approval in calendar Q1 2019]

CORPORATE STRUCTURE

CAPITAL STRUCTURE (ASX:MEB) (OTCQB: MDBIF)

Market Cap	**AU$12.4M**
Share Price *as of 30 September 2018*	AU$0.06
Shares on Issue	203M
Cash Available[1]	**AU$4.9M**

Significant Institutional Investors

- FIDELITY 9.1%
- REGAL FUNDS MANAGEMENT 6.8%
- IFM INVESTORS 4.5%

Shareholder Mix[3]

- PRIVATE HOLDERS 52%
- INSTITUTIONAL HOLDERS 42%
- BOARD AND MANAGEMENT 6%[4]

1. Estimated cash balance of $1.5M at September 30, 2018 plus anticipated inflows from grant funding and partly paid shares.
2. Percentage of shares on issue
3. Percentages based on available information, including share registry, options listing, ASX filings, and other reported data
4. Includes shares on issue and options

medibio

QUARTERLY CASH BURN REDUCTIONS



BOARD OF DIRECTORS

CHRIS INDERMAUR
Chairman
B. Eng. (Mech.), Grad Dip Eng. (Chem.), LLB, LLM, Grad Dip LP

PETER CARLISLE
Vice Chairman
Managing Director, Olympics & Action Sports, Octagon Worldwide

DR FRANKLYN G PRENDERGAST
PhD MD, Non Executive Board Member
Former member board of Trustee and Board of Governors Mayo Clinic and board member Eli Lilly

PATRICK KENNEDY
Non Executive Director
Former US Congressman
Founder, Kennedy Forum

MICHAEL PHELPS
Non Executive Director
Mental Health Advocate

ANDREW MAXWELL
Non Executive Director
MBA, MAcc, ACPA

BRIAN MOWER
Interim CEO and CFO
B.S., MAcc, CPA

MELANIE LEYDIN
Company Secretary
B. Bus. (UTS), Grad. Dip. DP (UTS), CA, AGIA

medibio

EXECUTIVE TEAM

ARCHIE DEFILLO
Chief Medical Officer

Lindsey Hagen
Vice President Integrated Health

JEREMY SCHROETTER
Chief Technology Officer

Jennifer Solitario
Senior Vice President Corporate Health

PATRICK MIDDEN
Chief Privacy Officer

medibio

THE CHALLENGE

21 million suicide attempts from mental illness. Of those, nearly 1 million are successful

THE SOLUTION

End to end solutions for mental healthcare

THE SCIENCE

20+ years of scientific rigor

THE COMPANY

Ready to change the way the world looks at Mental Health,

OBJECTIVELY!

THE OPPORTUNITY

Corporate Health
64 million employees

Consumer Health
266 million lives

Integrated Health
450 million lives

THANK YOU

Brian Mower
Interim CEO and CFO
Brian.Mower@Medibio.com.au
8696 Eagle Creek Circle
Savage . MN 55378 USA